April 23, 2018
- Apellis Pharmaceuticals Announces Closing of Offering of Common Stock
April 18, 2018
- Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock
April 16, 2018
- Apellis Pharmaceuticals Announces Proposed Offering of Common Stock
April 16, 2018
- Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
March 19, 2018
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
February 23, 2018
- Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
February 22, 2018
- Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
January 2, 2018
- Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
December 20, 2017
- Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
December 19, 2017
- Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer
Displaying 1 - 10 of 25 results